Keros Therapeutics, Inc. (KROS)
11.23
+0.16
(+1.45%)
USD |
NASDAQ |
Sep 02, 16:00
11.23
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Cash from Investing (Quarterly) : -0.155M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.155M |
| March 31, 2026 | -0.073M |
| December 31, 2025 | -0.134M |
| September 30, 2025 | -0.132M |
| June 30, 2025 | -0.72M |
| March 31, 2025 | -0.565M |
| December 31, 2024 | -0.289M |
| September 30, 2024 | -0.386M |
| June 30, 2024 | -0.31M |
| March 31, 2024 | -0.946M |
| December 31, 2023 | -0.541M |
| September 30, 2023 | -0.55M |
| June 30, 2023 | -0.311M |
| March 31, 2023 | -1.062M |
| December 31, 2022 | -0.351M |
| Date | Value |
|---|---|
| September 30, 2022 | -0.176M |
| June 30, 2022 | -0.567M |
| March 31, 2022 | -0.147M |
| December 31, 2021 | -0.159M |
| September 30, 2021 | -0.145M |
| June 30, 2021 | -0.51M |
| March 31, 2021 | -0.21M |
| December 31, 2020 | -0.06M |
| September 30, 2020 | -0.03M |
| June 30, 2020 | -0.028M |
| March 31, 2020 | -0.176M |
| December 31, 2019 | -0.018M |
| September 30, 2019 | -0.082M |
| June 30, 2019 | -0.171M |
| March 31, 2019 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Incyte Corp. | -51.79M |
| Nurix Therapeutics, Inc. | 93.00M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.42M |
| Cash from Financing (Quarterly) | -3.315M |
| Free Cash Flow | -48.49M |
| Free Cash Flow Per Share (Quarterly) | -1.039 |
| Free Cash Flow to Equity (Quarterly) | -19.99M |
| Free Cash Flow to Firm (Quarterly) | -20.58M |
| Free Cash Flow Yield | -16.10% |